PMID- 15455259
OWN - NLM
STAT- MEDLINE
DCOM- 20060912
LR  - 20211116
IS  - 0172-8172 (Print)
IS  - 0172-8172 (Linking)
VI  - 26
IP  - 2
DP  - 2005 Dec
TI  - Induction of vascular endothelial growth factor and matrix metalloproteinase-3 
      (stromelysin) by interleukin-1 in human articular chondrocytes and synoviocytes.
PG  - 93-8
AB  - We investigated the effects of interleukin (IL)-1 on vascular endothelial growth 
      factor (VEGF) and matrix metalloproteinase-3 (MMP-3) (stromelysin) secretion from 
      chondrocytes and synoviocytes in different clinical conditions. Specifically, 
      cells obtained from osteoarthritic (OA) (n = 7), rheumatoid arthritic (RA) (n = 
      5), and post-traumatic (PT) (n = 5) patients were stimulated in vitro with 
      IL-1beta in the presence or absence of an IL-1 receptor antagonist (IL-1ra) 
      (anakinra). Levels of secreted MMP-3 and VEGF were measured by enzyme-linked 
      immunosorbent assay. The VEGF mRNA expression was analyzed quantitatively. 
      Interleukin-1 induced both VEGF and MMP-3 secretion from all of the samples 
      tested, and VEGF mRNA expression was also upregulated. Interleukin-1ra 
      significantly suppressed the enhancing effect of IL-1 on MMP-3 and VEGF in both 
      cell types. In conclusion, IL-1 simultaneously induces MMP-3 and VEGF production 
      from chondrocytes and synoviocytes in inflammatory, degenerative, and 
      post-traumatic joints. Therefore, IL-1ra might be beneficial for protection from 
      VEGF-mediated alterations of cartilage metabolism in pathologic and physiologic 
      conditions.
FAU - Inoue, Kenji
AU  - Inoue K
AD  - Division of Molecular Regulation, Department of Bioregulation, Institute of 
      Medical Science, St. Marianna University School of Medicine, 2-16-1 Sugao, 
      Miyamae-ku, Kawasaki-shi, Kanagawa 216-8512, Japan.
FAU - Masuko-Hongo, Kayo
AU  - Masuko-Hongo K
FAU - Okamoto, Masahiro
AU  - Okamoto M
FAU - Nishioka, Kusuki
AU  - Nishioka K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20040929
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Drug Combinations)
RN  - 0 (IL1RN protein, human)
RN  - 0 (Interleukin 1 Receptor Antagonist Protein)
RN  - 0 (Interleukin-1)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Interleukin-1)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Sialoglycoproteins)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cartilage, Articular/*drug effects/pathology
MH  - Cells, Cultured
MH  - Chondrocytes/*drug effects/metabolism/pathology
MH  - Drug Combinations
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Gene Expression/drug effects
MH  - Humans
MH  - Interleukin 1 Receptor Antagonist Protein
MH  - Interleukin-1/*pharmacology
MH  - Male
MH  - Matrix Metalloproteinase 3/*biosynthesis/genetics
MH  - Middle Aged
MH  - Osteoarthritis, Hip/metabolism/pathology
MH  - Osteoarthritis, Knee/metabolism/pathology
MH  - RNA, Messenger/metabolism
MH  - Receptors, Interleukin-1/antagonists & inhibitors
MH  - Recombinant Proteins/pharmacology
MH  - Sialoglycoproteins/pharmacology
MH  - Synovial Membrane/*drug effects/metabolism/pathology
MH  - Vascular Endothelial Growth Factor A/*biosynthesis/genetics
EDAT- 2004/09/30 05:00
MHDA- 2006/09/13 09:00
CRDT- 2004/09/30 05:00
PHST- 2003/12/29 00:00 [received]
PHST- 2004/06/30 00:00 [accepted]
PHST- 2004/09/30 05:00 [pubmed]
PHST- 2006/09/13 09:00 [medline]
PHST- 2004/09/30 05:00 [entrez]
AID - 10.1007/s00296-004-0513-6 [doi]
PST - ppublish
SO  - Rheumatol Int. 2005 Dec;26(2):93-8. doi: 10.1007/s00296-004-0513-6. Epub 2004 Sep 
      29.